Novartis
$141.00Change from previous close: −0.04%Absolute change: −$0.05
At a glance
- Revenue growth
- +9.57%
- 2025 vs 2024
- Net income growth
- +17.11%
- 2025 vs 2024
- Net margin
- 24.7%
- 2024: 23.1%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 5,882 | 3,676 | 2,264 | 6,571 | 6,664 | 3,645 | 4,193 | 6,286 | 4,875 | 2,265 | 2,547 | 5,378 |
| Depreciation and amortization | 1,200 | 1,189 | 1,175 | 1,259 | 1,160 | 1,150 | 1,165 | 1,162 | 1,116 | 1,156 | 1,146 | 1,316 |
| Capital expenditure | -321 | -346 | -609 | -354 | -331 | -254 | -558 | -321 | -260 | -227 | -406 | -261 |
| Investing cash flow | -3,105 | -11,736 | -2,104 | -860 | -2,243 | 330 | -3,033 | -374 | -3,207 | -899 | -1,760 | -2,212 |
| Financing cash flow | -2,020 | 3,579 | 1,683 | -2,789 | -5,213 | -8,548 | -2,996 | -382 | -3,200 | -5,164 | -607 | -832 |
| Dividends paid | -2,871 | -6,197 | 0.0 | — | -2,485 | -5,333 | 0.0 | — | -2,417 | -5,207 | — | — |
| Share repurchases | -1,199 | -1,875 | -1,480 | -2,302 | -2,714 | -2,716 | -2,762 | -2,854 | -1,616 | -1,099 | -1,256 | -1,625 |
| Debt issued | 2,190 | 11,665 | 5,126 | 135 | 850 | 556 | -24.0 | 3,670 | 3,042 | 1,220 | 546 | — |
| Debt repaid | -87.0 | -92.0 | -1,843 | -646 | -669 | -1,079 | -82.0 | -1,160 | -2,209 | -67.0 | 64.0 | -2,704 |
| Effect of exchange rates | -18.0 | -77.0 | 36.0 | -22.0 | 382 | 180 | -314 | 176 | -34.0 | -126 | 160 | -166 |
| Net change in cash | 739 | -4,558 | 1,879 | 2,900 | -410 | -4,393 | -2,150 | 5,706 | -1,566 | -3,924 | 988 | 1,520 |
| Free cash flow | 5,561 | 3,330 | 1,655 | 6,217 | 6,333 | 3,391 | 3,635 | 5,965 | 4,615 | 2,038 | 2,141 | 5,117 |
| Levered free cash flow | 2,037 | 4,332 | -178 | 5,190 | 2,149 | 4,422 | 3,716 | 4,067 | 1,608 | 2,643 | -1,762 | 12,493 |